Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-Rich Plasma

    May 2021 in “ Journal of Health Sciences ”
    Karina Karina, Krista Ekaputri, Johannes Albert Biben, Ratna Herawati Purwoko, Tommy P. Sibuea, Sarah Listyo Astuti, Anastasia Maria Loho, Yuliardy Limengka, Nelfidayani, S Agustini, Grady Krisandi, Azza Maryam, Imam Rosadi, Iis Rosliana, Siti Sobariah, Wismo Reja Subroto, Irsyah Afini, Tias Widyastuti, Alfida Zakiyah, Difky Ernanda, Noor Aini, Jusryanti, Sulaeha Ad, Sristin Indah Prestiani, Indah Mustika Donna, Habibi Habibi, Meyla Shinta Mutiara
    New to Platelet-Rich Plasma? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary In this study, researchers administered intravenous autologous activated platelet-rich plasma (aaPRP) to 611 patients and reported no adverse events, suggesting that this treatment is safe even for patients with various pathological conditions. Our plain-language summary of this paper — not a Tressless recommendation.
    The study titled "Evaluating the Safety of Intravenous Delivery of Autologous Activated Platelet-rich Plasma" aimed to assess the safety of intravenous administration of autologous activated platelet-rich plasma (aaPRP). The study involved 611 patients who underwent a total of 4244 aaPRP therapies. The aaPRP was isolated from each patient's blood through calcium activation and light irradiation, and then administered intravenously. The study found no adverse events such as allergic reactions, infections, or coagulation problems in any of the patients over the course of the study. Therefore, the study concluded that intravenous administration of autologous aaPRP is safe even in patients with various pathological conditions.
    Discuss this study in the Community →